Canada Influenza Vaccine Market Size & Outlook, 2023-2030
Canada influenza vaccine market, 2018-2030 (US$M)
Related Markets
Canada influenza vaccine market highlights
- The Canada influenza vaccine market generated a revenue of USD 426.6 million in 2023 and is expected to reach USD 711.4 million by 2030.
- The Canada market is expected to grow at a CAGR of 7.6% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 426.6 million |
| Market revenue in 2030 | USD 711.4 million |
| Growth rate | 7.6% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, Canada accounted for 5.4% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 711.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada influenza vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza vaccine market will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 92.33% in 2023. Horizon Databook has segmented the Canada influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is anticipated to witness exponential growth opportunities owing to high disease burden of influenza and increasing awareness of vaccination among the population. According to data published by Health Canada, 16,126 laboratory-confirmed influenza detections were reported during the 2021- 2022 influenza season.
Thus, the high burden of the disease is pushing government bodies to implement certain initiatives to combat influenza. For instance, in July 2022, the government of Manitoba, Canada, announced an expansion of eligibility for the high-dose influenza vaccine to include adults aged 65 years and above for enhanced protection from a life-threatening infection.
Moreover, recent product approvals and ongoing partnerships between market players & governments to increase vaccine supply are other factors propelling the market. For instance, in July 2022, GSK plc signed an agreement with the Government of Canada for seasonal and pandemic influenza vaccines to help protect Canadian children.
Reasons to subscribe to Canada influenza vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada influenza vaccine market databook
-
Our clientele includes a mix of influenza vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada influenza vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Canada influenza vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Canada influenza vaccine market size, by vaccine type, 2018-2030 (US$M)
Canada Influenza Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
